Integrated guidance for enhancing the care of Familial Hypercholesterolaemia in Australia by Watts, Gerald F. et al.
Heart, Lung and Circulation (2021) 30, 324–349
1443-9506/20/$36.00
https://doi.org/10.1016/j.hlc.2020.09.943
CONSENSUS STATEMENTIntegrated Guidance for Enhancing the
Care of Familial Hypercholesterolaemia in
Australia$
Gerald F. Watts, DSc (Lond), FRACP, FCSANZ a,b,*,1,2,
David R. Sullivan, FRACP, FRCPA, FCSANZ c,d,1,2,
David L. Hare, DPM, FRACP, FCSANZ e,f,1,2,
Karam M. Kostner, PhD, FRACP, FCSANZg,1,2,
Ari E. Horton, FRACP, FCSANZh,i,j,1,2,
Damon A. Bell, PhD, FRACP, FRCPA a,b,k,l,m,2,
Tom Brett, MD, FRACGP, MRCGPn,2,
Ronald J. Trent, DPhil (Oxon), FRACP, FRCPAo,p,2,
Nicola K. Poplawski, MD, MBChB, FRACP q,r,2,
Andrew C. Martin, MD, FRACP s,t,2, Shubha Srinivasan, PhD, FRACPu,v,2,
Robert N. Justo, FRACP, FCSANZw,x,2,
Clara K. Chow, PhD, FRACP, FCSANZ y,z,A,2, Jing Pang, PhD a,1,2,
and other members of FH Australasia Network Consensus Working Group3
aSchool of Medicine, Faculty of Health and Medical Sciences, University of Western Australia, Perth, WA, Australia
bLipid Disorders Clinic, Cardiometabolic Service, Departments of Cardiology and Internal Medicine, Royal Perth Hospital, Perth, WA, Australia
cDepartment of Chemical Pathology, Royal Prince Alfred Hospital, Sydney, NSW, Australia
dSydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia
eFaculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Vic, Australia
fDepartment of Cardiology, Austin Health, Melbourne, Vic, Australia
gDepartment of Cardiology, Mater Hospital, University of Queensland, Brisbane, Qld, Australia
hMonash Heart and Monash Children’s Hospital, Monash Health, Melbourne, Vic, Australia
iMonash Cardiovascular Research Centre, Melbourne, Vic, Australia
jDepartment of Paediatrics, Monash University, Melbourne, Vic, Australia
kDepartment of Clinical Biochemistry, PathWest Laboratory Medicine WA, Royal Perth Hospital and Fiona Stanley Hospital Network, Perth,
WA, Australia
lDepartment of Clinical Biochemistry, Clinipath Pathology, Perth, WA, Australia
mSonic Genetics, Sonic Pathology, Sydney, NSW, Australia
nGeneral Practice and Primary Health Care Research, School of Medicine, University of Notre Dame Australia, Fremantle, WA, Australia
oDepartment of Medical Genomics, Royal Prince Alfred Hospital, Sydney, NSW, Australia
pCentral Clinical School, Faculty of Medicine and Health, University of Sydney, NSW, Australia
qAdult Genetics Unit, Royal Adelaide Hospital, Adelaide, SA, Australia
rAdelaide Medical School, University of Adelaide, Adelaide, SA, Australia* Corresponding author at: Professor Gerald F. Watts, School of Medicine, Faculty of Health and Medical Sciences, University of Western Australia, GPO Box X2213
Perth, WA 6847, Australia; Email: gerald.watts@uwa.edu.au
1Steering Committee.
2Writing Committee.
3Other Contributors listed at end of article.
$This guidance has been endorsed by the Australian Atherosclerosis Society, Cardiac Society of Australia and New Zealand, National Heart Foundation (Australia),
Australian Cardiovascular Alliance, Human Genetics Society of Australasia, European Atherosclerosis Society, International Atherosclerosis Society, FH Foundation,
Heart UK, Asian-Pacific Society of Atherosclerosis and Vascular Disease, National Lipid Association (US) and the American Society of Preventive Cardiology.
 2020 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ).
Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Integrated Guidance for Enhancing the Care of FH in Australia 325sDepartment General Paediatrics, Perth Children’s Hospital, Perth, WA, Australia
tDivision of Paediatrics, Faculty of Health and Medical Sciences, University of Western Australia, Perth, WA, Australia
uInstitute of Endocrinology and Diabetes, The Children’s Hospital at Westmead, Sydney, NSW, Australia
vDiscipline of Child and Adolescent Health, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia
wDepartment of Paediatric Cardiology, Queensland Children’s Hospital, Brisbane, Qld, Australia
xSchool of Medicine, University of Queensland, Brisbane, Qld, Australia
yWestmead Applied Research Centre, The University of Sydney, Sydney, NSW, Australia
zDepartment of Cardiology, Westmead Hospital, Sydney, NSW, Australia
AGeorge Institute for Global Health, Sydney, NSW, AustraliaFamilial hypercholesterolaemia (FH) is a dominant and highly penetrant monogenic disorder present
from birth that markedly elevates plasma low-density lipoprotein (LDL)-cholesterol concentration and,
if untreated, leads to premature atherosclerosis and coronary artery disease (CAD). There are
approximately 100,000 people with FH in Australia. However, an overwhelming majority of those
affected remain undetected and inadequately treated, consistent with FH being a leading challenge for
public health genomics. To further address the unmet need, we provide an updated guidance, pre-
sented as a series of systematically collated recommendations, on the care of patients and families with
FH. These recommendations have been informed by an exponential growth in published works and
new evidence over the last 5 years and are compatible with a contemporary global call to action on FH.
Recommendations are given on the detection, diagnosis, assessment and management of FH in adults
and children. Recommendations are also made on genetic testing and risk notification of biological
relatives who should undergo cascade testing for FH. Guidance on management is based on the con-
cepts of risk re-stratification, adherence to heart healthy lifestyles, treatment of non-cholesterol risk
factors, and safe and appropriate use of LDL-cholesterol lowering therapies, including statins, ezeti-
mibe, proprotein convertase subtilisin/kexin type 9 inhibitors and lipoprotein apheresis. Broad rec-
ommendations are also provided for the organisation and development of health care services.
Recommendations on best practice need to be underpinned by good clinical judgment and shared
decision making with patients and families. Models of care for FH need to be adapted to local and
regional health care needs and available resources. A comprehensive and realistic implementation
strategy, informed by further research, including assessments of cost-benefit, will be required to ensure
that this new guidance benefits all Australian families with or at risk of FH.Keywords Familial hypercholesterolaemia  Guidance  Adults  Children  Diagnosis  Assessment  Genetic testing





Indisputable evidence confirms the causal role of low-density
lipoprotein (LDL) particles in the initiation and development
of atherosclerotic cardiovascular disease (ASCVD) [1,2]. The
classical feature of familial hypercholesterolaemia (FH) is a
marked elevation in plasma LDL-cholesterol concentration
from birth due to highly penetrant monogenic defects that
impair the hepatic clearance of LDL-cholesterol via the LDL
receptor [3,4]. FH is themost common co-dominantly inherited
cause of premature ASCVD, principally coronary artery dis-
ease (CAD). Accordingly, FH is characterised clinically by a
personal and family history of hypercholesterolaemia and
early CAD [3]. The genetically mediated risk of ASCVD starts
to increase from birth and extends over the lifespan. If un-
treated, the accumulatedburdenofLDL-cholesterol acceleratesthe onset of CAD in both men and women of every race and
ethnicity [1,3]. The contemporary care of FH provides an
exemplarof thevalueof precisionmedicine in thepreventionof
premature ASCVD in families [3–5].
Importance of FH: Tier 1 Genomic
Application
Recent epidemiological studies indicate that the overall
prevalence of FH in the general population may be as high as
1 in 250 [6–8]. This implies that currently there are approxi-
mately 100,000 Australians living with the condition, one in
five of whom are children. The prevalence of FH is especially
high among people with premature ASCVD [7,8]. The Cen-
ters for Disease Control and Prevention have appropriately
defined FH as a tier 1 genomic application [5,9], meaning
that there is strong evidence that it is a preventable cause of
premature disease and death, with significant potential for
positive impact on public health and health care savings
[7,8,10]. FH is more prevalent than other tier 1 genomic ap-
plications, such as hereditary breast and ovarian cancer and
Figure 1 Architecture of the integrated guidance for enhancing the care of patients and families with familial hyper-
cholesterolaemia (FH). The individual recommendations for each of the major components of the guidance are numbered in
each box in the Figure and detailed in Tables 1–9.
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cer) [5,9]. However, in spite of the importance of FH, less
than 10% of individuals (particularly children and adoles-
cents) have been detected, and of those treated, over 80% do
not attain guideline recommended LDL-cholesterol targets
[3,5]. Targeting the detection of FH as a priority in children
and the young could have the greatest impact on the pre-
vention of ASCVD [11–13].
Guidelines, Position Statements and
Models of Care on FH
The wide gaps in the care of FH have led to the publi-
cation of several international guidelines and position
statements [11,14–19]. The FH Australasia Network pub-
lished one of the first models of care for FH in 2011 [17].
This model was conceived as an adaptive and integrated
system, based on theoretical and evidence-based stan-
dards, providing the highest quality of health care services
to patients and families with FH [17]. Such a framework
allows the incorporation of evolving evidence to inform
new standards of care, which form the basis for the pre-
sent guidance. Our original model of care for FH [17] was
significant in informing several international guidelines on
FH [11,12]. It was updated by an international group of
experts [18] and informed a scientific statement from the
American Heart Association [11]. The 2014 integrated
guidance [18] was assessed using the Appraisal of
Guidelines for Research & Evaluation Instrument (AGREE-
II) criteria by an independent group of international in-
vestigators and ranked as the leading contemporary
guidance on FH [20].Exponential Growth of Knowledge on
FH: Review of Evidence
Since publication of the aforementioned guidelines, there has
been an exponential growth in published works on several
aspects of FH [3]. This includes the following: new knowledge
on population prevalence [6–8]; screening methods [3,5,13,21]
including use of non-fasting samples [22]; the role of primary
care in detection and treatment [23]; new diagnostic gene
technologies and genetic testing protocols [24]; methods for
risk re-stratification, including estimation of lipoprotein(a)
[25–28] and non-invasive cardiovascular imaging [3,29,30];
screening and treatment of children [12,31,32]; the safety and
tolerability of statins [33,34]; the efficacy and application of
new therapies (eg. proprotein convertase subtilisin/kexin
type 9 inhibitors); management of homozygous FH including
use of lipoprotein apheresis [35–37]; comprehensive health
economic evaluations [38,39]; organisation of services [3],
clinical registries [40–42]; role of advocacy and patient sup-
port groups [43]; and, definitions of research programs
[3,11,44]. This evolving knowledge was reviewed systemati-
cally by representatives of the Writing Committee of this
guidance in collaboration with international experts in the
field in a period up to September 2019. As a consequence, two
reviews have been published [3,5] which summarise the
essential evidence which has enabled the development of the
new recommendations on FH (see Tables 1–9; Appendices A
and B; Supplementary Material: Tables 1–9; evidence for
statements listed and referenced [References 1–332]). Addi-
tional relevant studies published in 2020 were also employed
to support guidance statements. Beyond specific guidelines
on FH [11,14–19], our recommendations have also been based
Table 1 Phenotypic detection of index cases: screening and testing strategies.
Class Level
1.1 Several strategies should be considered for detecting index cases of familial
hypercholesterolaemia (FH), including selective, opportunistic and universal screening
2 B
1.2 Index cases should be sought by selective screening of adults with premature atherosclerotic
cardiovascular disease (ASCVD), primarily coronary artery disease, and a family history of
premature ASCVD and/or hypercholesterolaemia
1 A
1.3 Opportunistic screening, based on a plasma low density lipoprotein (LDL)-cholesterol level
of .5.0 mmol/L, should be employed for detecting adults in primary care
1 B
1.4 Universal screening, based on a plasma LDL-cholesterol level .3.5 mmol/L, should be
considered before puberty (preferable between 1 to 2 yr of age, coinciding with childhood
immunisation) to initially detect children with FH (see 3.5 for diagnostic criteria and see 3.6 and
5.13 for testing of biological relatives)
2 B
1.5 Digital screening (based on key clinical criteria for FH, see Appendix D) of electronic health
records should be considered to enable case detection, particularly in primary care
2 B
1.6 Alerts and interpretive comments on laboratory reports on plasma lipid profiles should be
employed to enable case detection, including the need to make a phenotypic diagnosis of FH (see
Appendix D)
1 B
1.7 The Dutch Lipid Clinic Network (DLCN) criteria (see Appendix D) should only be used to
make a phenotypic diagnosis of FH in adults, ideally based on two fasting LDL-cholesterol
values estimated by Friedewald’s formula or a direct assay; the DLCN criteria should not be
used in children and adolescents
1 A
1.8 Non-fasting samples have practical advantages and may be used to approximate LDL-
cholesterol by Friedewald’s formula when screening for FH; however, they should be used with
caution in patients known to have hypertriglyceridaemia
3 B
1.9 In patients with triglycerides .4.5 mmol/L, LDL-cholesterol should be estimated by a direct
assay; the diagnosis of FH in such patients should also be based on a 12-hr fasting sample
1 A
1.10 If LDL-cholesterol cannot be measured with a direct assay owing to severe
hypertriglyceridaemia, the diagnosis of FH should be reconsidered after therapeutic lowering of
triglycerides to below 10 mmol/L
2 C
1.11 The effect of concurrent medication and significant acute illness on LDL-cholesterol should
be accounted for: LDL-cholesterol should be adjusted appropriately for use of statin and/or
ezetimibe after ensuring adherence to therapy (see Appendix D footnote), particularly if a
reliable pre-treatment value is not available; LDL-cholesterol should be repeated after full
recovery from acute illness, particularly if the diagnosis of FH is in doubt
1 B
1.12 All patients with suspected FH should be referred to or discussed with a specialist with
expertise in lipidology for further assessment (see 2.9, 3.6 and 3.11)
1 C
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ary prevention of ASCVD [49–52], as well as on meta-
analyses and systematic reviews on the role of LDL-
cholesterol in the inception and development of ASCVD
[2,53]. We acknowledge that several novel therapies are in
development for managing FH [54–58]. However, with the
exception of an angiopoietin-like protein 3 inhibitor for ho-
mozygous FH [58], none have been referred to in our rec-
ommendations. This is because these agents are still being
tested in clinical trials and are not registered in Australia.
National Health Genomics Policy
Framework
As reviewed elsewhere, the recommendations of the Na-
tional Health Genomics Policy Framework [59] have alsoinformed the recommendations for this new model of care
for FH. Priority areas include patient-centred approaches,
upskilling of the workforce in knowledge of genomics, cost-
effective use and evidence-based design of services, and the
need for high-quality data collection [59]. Our new recom-
mendations are aligned with the aforementioned priorities.
They will accordingly enhance the strategic approach for
incorporating genomics into the Australian health care sys-
tem, as also exemplified by other inherited heart conditions
[60]. Genetic testing for FH was listed on the Australian
Medicare Benefits Schedule (MBS) in 2020 [61], based on
recommendations by the national Medical Services Advisory
Committee [62] that were informed by robust cost-
effectiveness data collated from an Australian specialist
centre [38]. The present guidance includes specific
Table 2 Diagnosis and assessment of adults.
Class Level
2.1 Secondary causes of hypercholesterolaemia should be excluded before making a diagnosis of
familial hypercholesterolaemia (FH) (see Appendix E)
1 A
2.2 The diagnosis of FH should be made using both phenotypic criteria (see 1.7) and genetic
testing, but when genetic testing is not available the diagnosis should be made phenotypically
(see Appendix D)
1 A
2.3 Detection of subclinical Achilles tendon xanthomata, using standard imaging methods, may
be considered to further establish the phenotypic diagnosis of FH and to assess risk of
atherosclerotic cardiovascular disease (ASCVD)
3 B
2.4 When possible, genetic testing should be used to confirm the diagnosis of FH, especially if
cascade testing (see Tables 4 and 5) is planned
1 A
2.5 Patients with FH should be risk assessed for the presence of major ASCVD risk factors,
including elevated lipoprotein(a) [Lp(a)] (see 2.7), which should be employed to guide clinical
management
1 B
2.6 Cardiovascular risk prediction equations derived from the general population (eg. the
Australian absolute cardiovascular disease risk calculator) should not be used in patients with
FH
1 B
2.7 Lp(a) should be measured using an immunoassay that is independent of, and therefore not
affected by variation in, the isoform size of apolipoprotein(a); if this is not possible, Lp(a) should
be measured using an immunoassay validated as being minimally sensitive to apolipoprotein(a)
isoform size; all assays should be calibrated against the World Health Organization/
International Federation of Clinical Chemistry and Laboratory Medicine reference material;
results should be reported in nmol/L of Lp(a) particles, with increased risk of ASCVD defined as
.100 nmol/L
1 B
2.8 In asymptomatic adult patients with heterozygous FH, cardiovascular imaging, such as
coronary artery calcium score (CACS), computed tomography coronary angiography (CTCA)
and carotid ultrasonography, may be considered as clinically indicated for identifying
subclinical atherosclerosis, but the clinical value is not fully established
3 B
2.9 Adults with homozygous FH should be referred to a specialised centre for assessment and
planning of long-term care
1 A
2.10 Adults with homozygous FH should be referred to a cardiologist for clinical assessment and
evaluation of ASCVD burden with non-invasive imaging, such as CTCA, carotid
ultrasonography, and echocardiography (to assess atheromatous involvement of aortic valve
and root), as well as exercise stress testing or functional cardiac imaging, as clinically indicated
1 A
328 G.F. Watts et al.recommendations that will enable the appropriate use of




The quality of the new and diverse evidence in the literature
was evaluated systematically by the assigned Writing
Committee according to recommended protocols [45–48].
The totality of evidence was in turn systematically employed
to inform specific recommendations on the individual com-
ponents of the model of care of FH, accounting for prefer-
ences, values, circumstances and contexts where appropriate
[63–65]. The process and basis for the grading of the evidence
and recommendations are detailed in Appendices A and B[45–48]. Particular attention was given to include contribu-
tions from a wide spectrum of disciplines, consistent with a
multi-disciplinary approach, with health consumers ac-
counting for patient values and preferences [65,66]. The to-
tality of published works employed to develop the evidence-
informed statements and recommendations are given in the
Supplementary Material (Tables 1–9, statements’ evidence
references 1–332).
It should be emphasised that the evidence for therapeutic
interventions in FH was considered principally in respect of
the effects on plasma LDL-cholesterol concentration, but
where available, was also based on data on subclinical
atherosclerosis and atherosclerotic cardiovascular outcomes
[17,18]. As in previous publications [17,18], we considered
that the absence of randomised controlled trials in FH should
not diminish a strong recommendation for an intervention,
Table 3 Diagnosis and assessment of children and adolescents.
Class Level
3.1 As in adults, secondary causes of hypercholesterolaemia should be excluded before making a diagnosis of
familial hypercholesterolaemia (FH) (see Appendix E)
1 A
3.2 Children with xanthomata, or other stigmata, of homozygous FH, or at risk of homozygous FH, should be
tested as early as possible, at least by 2 yr of age
1 B
3.3 Testing of all children with suspected heterozygous FH using phenotypic and/or genotypic strategies should
be considered between the ages of 5 and 10 yr
2 B
3.4 The Dutch Lipid Clinical Network (DLCN) criteria should not be employed to make a diagnosis of FH in
children and adolescents (see 3.5)
1 A
3.5 A highly probable phenotypic diagnosis of FH should be considered according to the following criteria: (1) an
low density lipoprotein (LDL)-cholesterol of .5.0 mmol/L in the absence of a parental history of
hypercholesterolaemia or premature atherosclerotic cardiovascular disease (ASCVD), (2) an LDL-cholesterol of
4.0 to 5.0 mmol/L in the presence of a parental history of hypercholesterolaemia or premature ASCVD, or (3) an
LDL-cholesterol of .3.5 mmol/L, if a parent carries a pathogenic or likely pathogenic gene variant; LDL-
cholesterol should be based on at least two fasting LDL-cholesterol values
2 B
3.6 Children and adolescents with heterozygous FH should ideally be reviewed by a paediatric specialist with
expertise in lipidology and access to multi-disciplinary services
1 C
3.7 Genetic testing for FH should generally be offered to diagnose children after a pathogenic or likely pathogenic
gene variant has been identified in a parent or first-degree relative (see 4.3 for genetic testing of children as index
cases; see Table 5 for cascade testing and counselling)
1 B
3.8 Children with FH should be risk stratified according to age, presence of other ASCVD risk factors, family
history of premature ASCVD (especially in first-degree relatives) and the level of LDL-cholesterol and
lipoprotein(a) [Lp(a)] at diagnosis, which should collectively guide clinical management
1 B
3.9 In children and adolescents with heterozygous FH, measurement of carotid intima-medial thickness using
carotid ultrasonography (carried out in centres with relevant expertise) may be employed to assess ASCVD risk,
but its clinical value is not fully established
3 B
3.10 In children and adolescents with heterozygous FH, computed tomography coronary angiography (CTCA)
and coronary artery calcium score should not be used to assess ASCVD risk
1 C
3.11 Children and adolescents with homozygous FH should be referred on diagnosis to a paediatric centre with
expertise in the care of such patients for comprehensive assessment and planning of long-term care
1 A
3.12 Children and adolescents with homozygous FH should be reviewed by a paediatric cardiologist for clinical
assessment and evaluation of ASCVD burden with non-invasive imaging, such as CTCA and carotid
ultrasonography, as well as exercise testing or functional cardiac imaging, as clinically indicated
1 A
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lowering LDL-cholesterol (see Appendix B). For certain
statements where there was no evidence other than consis-
tency with best clinical practice, the argument from first
principles was employed by consensus, as in a previous
guidance [18], to define the evidence level (Appendices A
and B). Consistent with recent requirements for clinical
practice guidelines [65], we attempted to make our guidance
statements as practicable and implementable as possible.
Spectrum of Classes of Recommendations
and Levels of Evidence
We provide 140 statements in this new guidance on the care of
FH; 80 more than in our earlier work on FH [17]. Of the total
number of recommendations, 65.0% were classified as strong
(class 1), 16.4%asmoderate (class 2) and 18.6%asweak (class 3)
(see Appendix C). Of overall evidence levels, 25.0% were high(level A), 43.6% were moderate (level B) and 31.4% were low
(level C) (see Appendix C). High and moderate recommenda-
tions were generally supported by high andmoderate levels of
evidence (see Appendix C). The levels of evidence for this
guidance are compatible with and surpass many other
Australian clinical practice guidelines [65]. The evidence-poor
components clearly demonstrate that many decisions in the
care of FH patients need to be made with minimal or lower
quality evidence and that further research may be required
[3,11,44]. Compatible with the GRADE system [47], any
apparent discordance between level of evidence and class of a
recommendation reflected the perceived balance of benefits
versus risks or harm by following the recommendation, as
assessed by members of the Steering andWriting Committees
(Appendices A and B). It also reflected that for certain state-
ments further research was considered unlikely to change the
class of recommendation [47]. Beyond the published works
Table 4 Genetic testing.
Class Level
4.1 Diagnostic genetic testing and counselling for familial hypercholesterolaemia (FH) should
ideally be offered to all adult index cases who have a probable/definite phenotypic diagnosis by
the Dutch Lipid Clinic Network (DLCN) criteria (see Appendix D)
1 B
4.2 Diagnostic genetic testing in an adult index case may be considered when there is limited
information to establish an accurate phenotypic diagnosis of FH by the DLCN criteria
3 B
4.3 Diagnostic genetic testing of children, as potential index cases, should be considered and
offered when parents or first-degree relatives are unknown or deceased, or as part of a universal
screening program (see 1.4 and 5.13), or if specifically required to gain access to special therapies
for FH (see 7.23)
2 B
4.4 Genetic testing for FH should be carried out in an accredited laboratory using standardised
methods to detect pathogenic and likely pathogenic gene variants affecting the low density
lipoprotein (LDL)-receptor pathway, and ideally by massively parallel sequencing
1 A
4.5 Variants detected by genetic testing should be classified according to the American College of
Medical Genetics and Genomics standards and guidelines or a comparable classification, and
should be described in the report using the current Human Genome Variation Society
nomenclature
1 A
4.6 If a pathogenic, or likely pathogenic variant, is not detected, FH should not be excluded
particularly if the clinical phenotype is strongly suggestive of FH, as the condition may be due to
undetected genetic variants
1 A
4.7 Use of polygenic risk scores may be useful in differential diagnosis and risk re-stratification,
but their precise value in the management of FH remains to be determined and they should be
used with caution
3 B
4.8 Diagnostic genetic testing of index cases with suspected FH should be requested by a
specialist with appropriate skills in the care of patients and families with FH (see. 1.12)
1 C
4.9 Where appropriate (eg. rural centres and remote regions), diagnostic genetic testing of index
cases with suspected FH may be requested by a general practitioner (GP) guided by a specialist
with appropriate skills in the care of patients and families with FH (see 1.12)
3 C
4.10 All health care professionals involved in consenting families for genetic testing and in the
clinical management of patients with FH should receive appropriate education in genomic
medicine and have basic skills in genetic counselling
1 C
4.11 Simple and pragmatic tools for counselling, consenting and disclosure of genetic
information should be developed and tested to support health care professions in providing
genetic testing
1 C
4.12 Where both members of a couple have or are at risk of FH, the couple should be referred to
genetic services for pre-conception counselling, including the offer of genetic testing if required,
discussion of reproductive risks and shared decision making on reproductive planning options
(including pre-natal testing and pre-implantation genetic diagnosis)
1 B
330 G.F. Watts et al.supporting the recommendations in this guidance
(Supplementary Material Tables 1–9, statements’ evidence
references 1–332), the clinical care of patients and families with
FH must be based on good clinical judgement and shared de-
cision making [66,67].
The Real Challenge: Translation and
Implementation of Models of Care
The updating of guidelines andmodels of care arewell aligned
with international calls to action on FH [10,68]. These have
emphasised the need to enhance awareness, advocacy,
screening, testing, diagnosis and treatment of FH, therebysolidifying and extending the 1999 WHO recommendations
[69]. The critical challenge that remains is translating the rec-
ommendations in this new guidance into health policy and
routine high-quality care for all individuals in the population
[70–72]. Implementation science affords a unique opportunity
for translating recommendations into routine practice to ach-
ievemaximal benefit for the population [71,73]. To optimise the
care of FHwithin the contexts of the complexAustralian health
care system and advances in genomic medicine [59,74], an
implementation strategy needs to account for the perspectives
and needs of all patients, families, health care providers,
stakeholder organisations, health policy makers and the
Table 5 Cascade testing and risk notification of families.
Class Level
5.1 Cascade testing (testing of consenting biological relatives of an individual with confirmed
familial hypercholesterolaemia [FH]) should be carried out using both a phenotypic and
genotypic strategy, but if genetic testing is not available a phenotypic strategy should be used
(see 5.3 and Appendix F).
1 A
5.2 Variant specific genetic testing is more cost-effective than phenotypic testing and should be
employed to screen family members after a pathogenic, or likely pathogenic, gene variant has
been identified in the family
1 A
5.3 When genetic testing is not feasible, the diagnosis of FH in close relatives should be made
phenotypically using age- and gender-specific plasma low density lipoprotein (LDL)-cholesterol
levels (see Appendix G); the Dutch Lipid Clinic Network (DLCN) criteria should not be
employed to make the diagnosis of FH in relatives
1 A
5.4 The process of risk notification of relatives, a crucial part of family care, should be consistent
with relevant local legislation and institutional guidelines; risk notification may be indirect
(providing a family letter for the notifier to pass to relatives) or direct (clinical service writes to
relatives)
1 C
5.5 Where consent for risk notification is refused and that notification carries a risk of breach of
confidentiality for the individual refusing, relatives should only be directly notified of their risk
if there is specific legislative provision for notification without consent
1 C
5.6 A pro-active approach that respects the principles of privacy, justice and autonomy should be
followed
1 C
5.7 Pre- and post-test genetic counselling should be offered to all at risk family members as an
integral component of cascade testing
1 A
5.8 Cascade testing and risk notification should ideally be co-ordinated by a well-resourced
centre, particularly if employing genetic testing
1 A
5.9 Genetic cascade testing may be undertaken by a general practitioner (GP) with skills in the
care of patients and families with FH, under the guidance of an appropriate specialist
3 C
5.10 Genetic cascade testing should initially be prioritised for first-degree relatives of a variant
carrier and sequentially extended as additional carriers are identified; if first-degree relatives
decline testing, genetic testing should be extended to second-degree followed by third-degree
relatives
1 A
5.11 Phenotypic cascade testing should initially be prioritised for first-degree relatives and
sequentially extended as additional affected individuals are identified; if first-degree relatives
decline testing, phenotypic cascade testing should be extended to second-degree followed by
third-degree relatives
1 A
5.12 Cascade testing should ideally be integrated with all strategies for the detection of index
cases (see 1.1 to 1.6 and 4.1)
1 B
5.13 Universal screening of children should be coupled with child-parent (reverse) cascade
testing (see 1.4 and 3.6)
1 B
5.14 Digital technologies should be developed and tested to enable the process of cascade testing
and risk notification of relatives
1 C
5.15 All health care professionals involved in cascade testing and risk notification of families
should receive specific training and have basic skills in counselling, as well as in genomic
medicine, especially if they are involved in genetic cascade testing
1 C
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research is essential for improving the outcomes of FHpatients
over their lifespan [3,10,70]. Implementation has to bemission-
driven to fully address the gaps between efficacious anddelivered care [71]. This methodology must be embraced and
adopted routinely to increase the impact of the new recom-
mendations on improving the care of FH as a national health
priority [10,70,75].
Table 6 Management of adults.
Class Level
6.1 All adult patients with familial hypercholesterolaemia (FH) should be offered counselling on
lifestyle modifications (eg. a fat-modified/heart healthy diet, regular physical exercise,
moderation in alcohol intake), interventions to address psychological issues (eg. adjustment
disorders, anxiety, depression) and advice to correct all non-cholesterol risk factors (eg. smoking,
hypertension, obesity, diabetes) should be provided according to expert recommendations (see
9.3, 9.4 and 9.5)
1 B
6.2 Management should be based on shared decision making and address patient values and
preferences; health literacy and barriers to treatment adherence should be addressed and a
personalised treatment plan devised
1 B
6.3 In all adult patients with heterozygous or homozygous FH, therapy should initially aim for at
least a 50% reduction in plasma low density lipoprotein (LDL)-cholesterol
1 B
6.4 After reaching the target in 6.3, the following therapeutic targets should be considered
according to a patient’s level of atherosclerotic cardiovascular disease (ASCVD) risk: (1) LDL-
cholesterol ,2.5 mmol/L (absence of ASCVD or other major ASCVD risk factors); (2) LDL-
cholesterol ,1.8 mmol/L (imaging evidence of ASCVD alone or other major ASCVD risk
factors); or (3) LDL-cholesterol ,1.4 mmol/L (presence of clinical ASCVD)
2 B
6.5 In FH patients who develop a recurrent ASCVD event within 2 yr on maximally tolerated
statins, a lower primary target for LDL-cholesterol of ,1.0 mmol/L may be considered
3 C
6.6 In FH patients with clinical ASCVD, the following secondary targets for therapy may be
considered: non-HDL cholesterol ,2.2 mmol/L and apolipoprotein B (apoB) ,0.65 g/L (stable
ASCVD), non-HDL cholesterol ,1.8 mmol/L and apoB ,0.5 g/L (recurrent ASCVD events)
3 C
6.7 Maximally tolerated high potency statins (eg. atorvastatin or rosuvastatin) with or without
ezetimibe, and a fat-modified, heart-healthy diet, with or without plant sterol (or stanol)
supplementation, should initially be employed to achieve the above treatment targets
1 A
6.8 A proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor should be employed if
treatment targets are not achieved with maximally tolerated statins, ezetimibe and diet
1 A
6.9 Bile acid sequestrants, niacin or fibrates may be considered to further lower LDL-cholesterol 3 B
6.10 If an adult patient with heterozygous FH aged between 18 and 30 yr has been treated from
childhood and does not have evidence of ASCVD, the LDL-cholesterol treatment target need not
be as intensive as above (see 6.3 and 6.4)
3 C
6.11 Fasting samples should be used to assess LDL-cholesterol responses to the initiation of and
change in drug therapy, as well as to monitor LDL-cholesterol in patients with unstable plasma
lipid profiles or elevated triglycerides
1 B
6.12 Non-fasting samples should be considered for convenience to monitoring LDL-cholesterol
in patients who are on stable drug therapy and do not have elevated triglycerides
2 B
6.13 Patients with statin intolerance should be assessed and investigated according to established
guidelines and should be treated with non-statin therapies, including ezetimibe and PCSK9
inhibitors, to achieve LDL-cholesterol treatment targets
1 A
6.14 Low-dose aspirin may be considered in asymptomatic FH patients at higher risk of ASCVD
(eg. not at LDL-cholesterol target, marked elevation in Lp(a), diabetes, adverse findings on
cardiovascular imaging) who are not predisposed to bleeding
3 C
6.15 In FH patients with clinical ASCVD, or diabetes, on maximally tolerated statins and
ezetimibe and with elevated triglyceride levels (1.5–5.6 mmol/L), the addition of high-dose,
high-purity omega-3 fatty acids (especially 4 g/d of pure eicosapentaenoic acid ethyl ester)
should be considered to further reduce ASCVD risk
2 B
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Table 6. (continued).
Class Level
6.16 Adult patients with FH should continue cholesterol-lowering drug therapies during acute
illness, such as respiratory infections, unless their use is specifically contra-indicated
1 C
6.17 Adult patients with FH, especially those with ASCVD or older than 65 yr, should be offered
influenza, pneumococcal and related vaccines as a preventive measure against respiratory
infections and acute ASCVD events
1 C
6.18 Plasma levels of hepatic aminotransferases, creatine kinase, glucose and creatinine should
be measured before starting and dose titrating drug therapy. All patients on statins should have
hepatic aminotransferases monitored; creatine kinase should be measured when musculoskeletal
symptoms are reported; glucose and glycated haemoglobin should be monitored, particularly if
there are risk factors for diabetes
1 B
6.19 All women of child-bearing age with FH should be offered pre-pregnancy counselling, with
individualised and appropriate advice on contraception to minimise cardiovascular risk, before
starting a statin and this should be reinforced at annual review
1 B
6.20 Statins and other systemically absorbed cholesterol regulating drugs should be discontinued
3 mo before planned conception, as well as during pregnancy and breastfeeding
1 B
6.21 In women with homozygous FH and clinical ASCVD, use of statins and ezetimibe may be
considered after the first trimester, particularly if lipoprotein apheresis is not feasible
3 B
6.22 Although coronary artery calcium score (CACS) may be useful for initial risk stratification in
asymptomatic patients with FH prior to commencing a statin (see 2.8), it should not be used to
monitor the efficacy of therapy
1 B
6.23 In asymptomatic patients with heterozygous FH, carotid ultrasonography and computed
tomography coronary angiography (CTCA) may be used for monitoring the efficacy of
cholesterol-lowering therapy, noting that the clinical value of these investigations is not fully
established
3 B
6.24 In adults with homozygous FH, carotid ultrasonography, CTCA, echocardiography and
exercise stress testing should be employed (every 5 yr or as clinically indicated) to assess
progression of coronary ASCVD, carotid ASCVD, atheromatous involvement of aortic valve/
root, and inducible myocardial ischaemia, respectively, with the aim of guiding overall
management, including the intensity of cholesterol-lowering therapy
1 B
6.25 Lomitapide and evinacumab may be considered, via special access or compassionate use
schemes, in all patients with homozygous FH and rapidly progressive ASCVD, as adjunctive
treatments to diet and other drugs, to further lower plasma LDL-cholesterol, particularly if
lipoprotein apheresis is not feasible
3 B
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Table 7 Management of children and adolescents.
Class Level
7.1 All patients and families with familial hypercholesterolaemia (FH) should be offered
counselling on lifestyle modifications (eg. a fat-modified/heart healthy diet, regular physical
exercise), interventions to address psychological issues, and advice to correct or prevent all non-
cholesterol risk factors (especially smoking); lifestyle counselling on primordial prevention (i.e.
the development of risk factors) is particularly important (see 7.16, 9.3 and 9.4)
1 B
7.2 Management should be based on shared decision making with parents and all children and
adolescents, with a developmentally appropriate and inclusive approach, and barriers to
treatment adherence addressed
1 B
7.3 In children and adolescents with heterozygous FH, the initiation of statin treatment should
be considered at age 8 to 10 yr irrespective of gender; plasma LDL-cholesterol targets in children
and adolescents need not be as intensive as in adults
2 B
7.4 Earlier initiation of treatment with statins (see 7.3) should be considered in FH patients with a
particularly adverse family history of atherosclerotic cardiovascular disease (ASCVD) (related
specifically to FH) or who have other major ASCVD risk factors (see 7.21 for statement on
homozygous FH)
2 B
7.5 In children with FH between the ages of 8 to 10 on a suitable diet, a treatment target of low
density lipoprotein (LDL)-cholesterol ,4.0 mmol/L or a 30–40% reduction in LDL-cholesterol
may be considered
3 C
7.6 In children with FH older than 10 yr on a suitable diet, a treatment target of LDL-cholesterol
,3.5 mmol/L or a 50% reduction in LDL-cholesterol may be considered
3 C
7.7 Statin therapy with or without ezetimibe, and a fat-modified/heart healthy diet, with or
without plant sterol (or stanol) supplementation, should be employed to achieve the above
treatment targets
1 A
7.8 Statins licenced in Australia for use in this age group should be employed: these include
pravastatin, fluvastatin and simvastatin; ezetimibe is licenced from the age of 10 yr and should
be used accordingly
1 A
7.9 The use of atorvastatin and rosuvastatin should be considered in heterozygous FH according
to clinical indications and shared decision making
2 A
7.10 The use of a proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitor may be considered
in heterozygous FH according to clinical indications and shared decision making, noting that
experience with and long-term safety of this drug class is limited in this age group
3 B
7.11 The use of maximal doses of potent statins and ezetimibe should be considered in
homozygous FH children as early as possible, ideally by the age of 2 yr
2 B
7.12 Fasting samples should be used to assess LDL-cholesterol responses to the initiation of and
change in drug therapy, as well as to monitor LDL-cholesterol in patients with unstable plasma
lipid profiles or elevated triglycerides
1 B
7.13 Non-fasting samples are particularly convenient in children and should be considered for
monitoring LDL-cholesterol in patients who are on stable drug therapy and do not have elevated
triglycerides
2 C
7.14 Although statins and ezetimibe can be safely used in children, weight, growth, physical and
sexual development, and well-being should be monitored in this age group
1 A
7.15 Plasma levels of hepatic aminotransferases, creatine kinase, glucose and creatinine should
be measured before starting and dose titrating drug therapy. All patients on statins should have
hepatic aminotransferases monitored; creatine kinase should be measured and compared to pre-
treatment levels when musculoskeletal symptoms are reported; glucose should be monitored,
particularly if there are risk factors for diabetes
1 B
7.16 All adolescent girls with FH should be offered pre-pregnancy counselling, with
individualised and appropriate advice on contraception to minimise cardiovascular risk, before
starting a statin and this should be reinforced at annual review
1 B
7.17 Shared care between paediatric specialists and general practitioners (GPs) should be
considered for managing well-controlled and lower complexity patients with FH
2 C
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Table 7. (continued).
Class Level
7.18 Management should focus on the nuclear or the immediate family, with at least an annual
review of children; non-adherence should be addressed
1 C
7.19 Transition of adolescents to young adult services should be considered early and planned in
advance, with particular support given to enable ongoing self-management and shared care into
adulthood
2 C
7.20 In children and adolescents with heterozygous FH, carotid ultrasonography (carried out in
centres with relevant expertise) may be employed to monitor therapy, but its clinical value is not
fully established
3 B
7.21 In children and adolescents with homozygous FH, treatment should commence as soon as
possible after diagnosis: the LDL-cholesterol target should be similar to adults (see 6.3 and 6.4),
which may require addition of a PCSK9 inhibitor to a statin and ezetimibe, as well as the use of
lipoprotein apheresis (see Table 8)
1 B
7.22 In children and adolescents with homozygous FH, computed tomography coronary
angiography (CTCA), carotid ultrasonography, echocardiography and exercise stress testing
should be employed as indicated (with a frequency determined by age, disease severity,
radiation exposure, or as clinically indicated) to assess progression of coronary ASCVD, carotid
ASCVD, atheromatous involvement of aortic valve/root, and inducible myocardial ischaemia,
respectively, with the aim of guiding overall management, including the intensity of cholesterol-
lowering therapy
1 B
7.23 Lomitapide and evinacumab may be considered, via special access or compassionate use
schemes, in all patients with homozygous FH and rapidly progressive ASCVD, as adjunctive
treatments to diet and other drugs, to further lower plasma LDL-cholesterol, particularly if
lipoprotein apheresis is not feasible
3 C
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Table 8 Lipoprotein apheresis and related treatments.
Class Level
8.1 Lipoprotein apheresis should be considered in all patients with homozygous or severe
heterozygous FH who cannot achieve low density lipoprotein (LDL)-cholesterol targets (see 6.3,
6.4 and 7.21) despite maximally tolerated drug therapy, including proprotein convertase
subtilisin/kexin type 9 (PCSK9) inhibitors
2 A
8.2 Lipoprotein apheresis should be considered in children with homozygous FH by the age of 5
and no later than 8 yr
2 B
8.3 Lipoprotein apheresis may be considered in adult heterozygous FH patients with progressive
clinical atherosclerotic cardiovascular disease (ASCVD) who cannot achieve LDL-cholesterol
targets despite maximally tolerated drug therapy, including PCSK9 inhibitors, and who have
residual elevation in lipoprotein(a) [Lp(a)] .150 nmol/L
3 C
8.4 Lipoprotein apheresis should be considered in pregnant women with homozygous or severe
heterozygous FH, especially those with clinical ASCVD in whom the use of cholesterol-lowering
therapy is not feasible
2 B
8.5 Lipoprotein apheresis should be carried out in a centre with relevant experience by trained
staff, who should be involved in regular multi-disciplinary team meetings
1 C
8.6 Use of existing clinical infrastructure (e.g. haemodialysis, transfusion, vascular surgery
services) should be considered for improving the quality and accessibility of apheresis services
2 C
8.7 If lipoprotein apheresis is not available or feasible (e.g. homozygous FH children with small
blood volumes), the use of therapeutic plasmapheresis (which is more widely available) may be
considered
3 C
8.8 Diet and drug therapy to lower LDL-cholesterol should be continued during treatment with
lipoprotein apheresis
1 A
8.9 Lipoprotein apheresis should be carried out using established techniques and procedures at a
frequency of once per wk or every 2 wk, according to feasibility, patient preferences and
achieved plasma LDL-cholesterol targets (see 6.3 and 6.4)
1 A
8.10 The efficacy of lipoprotein apheresis should be estimated as the time-averaged mean plasma
LDL-cholesterol concentration between sequential procedures using the Kroon formula, as
applicable to heterozygous and homozygous FH
1 B
8.11 The frequency of lipoprotein apheresis and intensity of combination drug therapy,
including use of a PCSK9 inhibitor (injected subcutaneously immediately after apheresis),
should be adjusted according to achieved LDL-cholesterol targets (see 6.4)
1 B
8.12 Reduction in the frequency, or discontinuation, of lipoprotein apheresis may be considered
when combination therapy with a PCSK9 inhibitor achieves an LDL-cholesterol well below the
recommended targets (see 6.4)
3 C
8.13 The efficacy, tolerability and safety of lipoprotein apheresis, as well as its impact on the
quality of life of patients, should be reviewed every few months or as clinically indicated
1 B
8.14 The effect of lipoprotein apheresis on progression of ASCVD should be monitored in FH
patients, as clinically indicated, using appropriate imaging modalities, including computed
tomography coronary angiography (CTCA), carotid ultrasonography and echocardiography (for
aortic valve and root involvement), as well as with exercise stress testing or functional cardiac
imaging (see 6.24 and 7.22)
1 B
8.15 Lomitapide and evinacumab may be considered, via special access or compassionate use
schemes, as an adjunctive to diet and other drugs, to further lower plasma LDL-cholesterol in
homozygous FH on lipoprotein apheresis (see 6.4, 6.8 and 8.11), particularly in patients who
have two LDL-receptor null alleles
3 B
8.16 Orthotopic liver transplantation should be considered for younger patients with
homozygous FH who have rapid progression of ASCVD or aortic stenosis, who cannot tolerate
lipoprotein apheresis (see 8.13), or whose plasma LDL-cholesterol cannot be adequately lowered
(see 6.3, 6.4, 7.21 and 8.9) with diet, drug treatment and lipoprotein apheresis
2 C
Abbreviation: PCSK9, proprotein convertase subtilisin/kexin type 9.
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Table 9 Organisation and development of care.
Class Level
9.1 The design and implementation of models of care for familial hypercholesterolaemia (FH)
should be based on the foundational principles of public health, as well as precision and
preventative medicine
1 A
9.2 Health care pathways should be developed to meet the needs of local, regional and remote
communities, and their acceptability to health consumers and health care professionals
(including primary care), as well as their cost-effectiveness and value, should be reviewed
regularly
1 C
9.3 Specialist services should be designed to cover a broad continuum of care for all patients with
FH, encompassing both public and private sectors, and should employ multi-disciplinary
strategies that are closely integrated with primary care
1 C
9.4 Specialist care should have access to lipidology, cardiology, endocrinology, paediatric,
genetic, imaging, transfusion medicine, nursing, dietetic, psychology, pharmacy practice,
pathology and telehealth services
1 C
9.5 General practice is central to the continuity of care of all FH patients and their families and
should accordingly be actively involved in screening, diagnosis, supporting families, shared care
with other specialties, managing cholesterol-lowering medication and multi-morbidities, and
implementing context-specific models of care for FH
1 C
9.6 Cascade testing and risk notification should ideally be undertaken by trained staff and co-
ordinated by a centralised service that is well-resourced (eg. includes clinical and allied health
staff, information technology and statistical support, telemedicine and educational facilities)
1 A
9.7 Cascade testing in primary care should be supported by adequate capacity and infrastructure
and collaborate closely with a centralised service (see 9.6)
1 C
9.8 Well controlled and lower complexity patients (see 2.5, 2.8 and 3.8) should, in most cases, be
managed in primary care
2 C
9.9 Less well-controlled and higher complexity patients (see 2.5, 2.9, 3.6, 3.8, 3.11, 3.12 and
Table 8) should be managed by specialists with expertise in the management of FH, with the
option of shared management with primary care
1 C
9.10 All health care professionals involved in the care of FH should receive appropriate
education and skills training in cardiovascular prevention, professional counselling and genomic
medicine (see Appendix H).
1 C
9.11 Services should establish partnerships with academic and professional organisations to
enhance teaching, training and research (see Appendix H)
1 C
9.12 The existing registry of patients and families (The FH Australasia Network Registry) should
be maintained for clinical, research and audit purposes; it should be developed to include
patient-centred capabilities, coverage of all health care services (including lipoprotein apheresis),
and linkage to other clinical quality and outcomes registries
1 C
9.13 The national coding systems for FH should be employed in primary and specialist care to
improve the precision of data acquisition and linkage, and their utilisation for audit, research
and development of health policy
1 C
9.14 The design of adaptive models of care should be underpinned by a research agenda that
includes population and basic science, clinical research, patient-centred research, and
implementation strategies
1 A
9.15 An advocacy and support group of patients and families should be established for
enhancing public, government and health care provider awareness, as well as for improving the
total quality of care of FH
1 B
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338 G.F. Watts et al.Summary of Guidance Statements
Tables 1 to 9 summarise the Guidance Statements for
Enhancing the Care of Familial Hypercholesterolaemia.
 Classes of Recommendation are included (1 = Strong, 2 =
Moderate, and 3 = Weak); as are,
 Levels of Evidence (A= High, B = Moderate, and C= Low).
Conversion Factors relevant for some Statements are:
 Low density lipoprotein (LDL)-cholesterol: conversion
from mmol/L to mg/dL, multiply mmol/L by 38.67;
 Triglycerides: conversion from mmol/L to mg/dL,
multiply by 88.57.
For details of consensus process, assessment of evidence and
development of recommendations, see Appendices A and B;
for the supportive evidence see the Supplementary Material
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Appendix A. Author provenance, evidence review, consensus process, and endorsements
Selection of Committees and Contributors
The Steering and Writing Committees were selected by board members of the Registry of FH Australasia Network (Australian
Atherosclerosis Society, AAS) for having expertise in lipidology, cardiology, pathology, genetics, dietetics, endocrinology,
general practice and paediatrics. Contributors were selected from a wide spectrum of medical and allied health specialties,
including general practice, general internal medicine, genomic medicine, nursing, pharmacy practice, and health consumers from
advocacy groups to account for variability in patient values and preferences; researchers with relevant expertise in genetics,
implementation science, health economics and FH also contributed to the document.
Evidence Review
The Steering Committee decided collectively that the structure of and approach to this guidance should be based on a previous
guidance on FH that had received a top ranking by an independent group employing the Appraisal of Guidelines for Research &
Evaluation Instrument (AGREE-II) assessment criteria [20]. The evidence for the development of this new guidance was based on
two peer-assessed reviews of FH [3,5], that were co-authored by members of the steering committee, as well as on additional
published works. For the review papers, a literature search of the English language was undertaken between January 2014 and
September 2019. The search employed the PubMed database with search string (all fields) “familial hypercholesterolemia” or
“familial hypercholesterolaemia”. GFW and JP assessed the titles and abstracts of all the articles identified and selected those that
were most novel and valuable for informing the components of the model of care for FH. Additional published works were
searched for using the above search terms in 2020 to generate relevant publications, which were also provided ad hoc by the
Writing Committee and by individual contributors up to 31 May 2020.
To update the guidance, the Writing Committee employed these publications, as well as specialist clinical experience and
expert opinion. The published works which informed the evidence and recommendations are shown in the Supplementary
Material (Tables 1–9; 332 references). The first draft of the guidance statements was produced by GFW and JP. Four (4) core
workshops chaired by GFW were held by video conference between December 2019 and January 2020. The fourth workshop
focussed exclusively on paediatric aspects of FH. The workshops include all members of the Steering Committee and members of
the Writing Committee that covered the essential sub-specialties. The agenda focussed on discussion of the evidence and
statement development, and consolidated the statements for each of the recommendations, which were designated both a Class
of Recommendation and a Level of Evidence according to the protocol in Appendix B. (see Supplementary Material for refer-
ences to the evidence supporting the statements). The totality of the evidence was assessed to inform the recommendations.
Document Review and Approval
The majority view (.80%) was employed to reach a consensus on the Class of Recommendation and Level of Evidence on the
earlier drafts of the guidance. The statements were reviewed and edited by smaller sub-specialty working groups (specifically in
genetic testing, cascade testing, risk notification, cardiovascular imaging, general practice and primary care). These discussions
were arranged by the chair via telephone or email communication. All revised statements were subsequently circulated to all
contributors for comment. Specific queries and disagreements with statements were resolved via telephone or email discussion
with GFW, who then reached full agreement, via email and/or videoconference, with members of the Steering and the Writing
Committees, as indicated by specialty. The writing committee examined the pre-final draft of the guidance and reached full
consensus on the recommendations and wording of statements. All contributors reviewed and commented on evolving drafts of
the document and approved the final version before submission.
Endorsements
Prior to publication, the full FH guidance with Supplementary Material was reviewed for endorsement by assigned members of
the Cardiac Society of Australia and New Zealand (CSANZ), National Heart Foundation (Australia), Australian Cardiovascular
Alliance, Human Genetics Society of Australasia, European Atherosclerosis Society, International Atherosclerosis Society, FH
Foundation, Heart UK, Asian-Pacific Society of Atherosclerosis and Vascular Disease, National Lipid Association (US) and the
American Society of Preventive Cardiology.
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Appendix B. Classes of Recommendations and Levels of Evidence used to develop the guidance on FH.
Classes of Recommendationsa
Strong recommendation: There is high certainty based on the evidence that the net benefit is
substantial
Wording: Should be performed; can be trusted to guide practice
Strong = 1
Moderate recommendation: There is moderate certainty based on the evidence that the net
benefit is moderate to substantial, or there is high certainty that the net benefit is moderate
Wording: Should be considered; can be trusted to guide practice in most situations
Moderate = 2
Weak recommendation: There is at least moderate certainty based on the evidence that there is a
small net benefit
Wording: May be considered; can be trusted to guide practice, but care should be taken in its application
Weak = 3
Levels of Evidenceb
Highly certain about the estimate of effect; further research is unlikely to change our confidence
in the estimate of effect
Basis: Randomised-controlled trials/meta-analyses/systematic reviews/good quality diagnostic studies
High = A
Moderately certain about the estimate of effect; further research may have an impact on our
confidence in the estimate of effect and may change the estimate
Basis: Good quality clinical or observational studies
Moderate = B
Low certainty about the estimate of effect; further research is likely to have an impact on our
confidence in the estimate of effect and is likely to change the estimate
Basis: Expert opinion based on clinical experience or argument from first principlesc
Low = C
The above systems for grading recommendations and evidence was agreed by consensus at workshops on the development of lipid position statements, held by
the Australian Atherosclerosis Society (AAS) in 2018, attended by members of the Steering Committee, members of the AAS Clinical Council and various
contributors.
The published works employed as evidence to support individual recommendations are specified in the Supplementary Material (Tables 1 to 9, and References 1
to 332).
aThis system was based on the American Heart Association/American College of Cardiology [45] and the National Lipid Association [46] cholesterol guidelines.
bThis system was based on the American Heart Association/American College of Cardiology [45] and the National Lipid Association [46] cholesterol guidelines,
and adapted from the original GRADE system of evidence rating [47], which is in turn endorsed by the National Health and Medical Research Council Guidelines
for Guidelines [48].
cArgument from first principles were employed for Statements 4.10, 5.4, 5.5, 5.6, 5.15, 9.7 and 9.10 (see Supplementary Material).
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Appendix C. Distributions of classes of recommendation and levels of evidence for each major component of the guidance
on FH.a,b
Classes of Recommendation:
0% 20% 40% 60% 80% 100%
Phenotypic Detection of Index cases: Screening and 
Testing Strategies (n=12)
Diagnosis and Assessment of Adults (n=10)
Diagnosis and Assessment of Children and 
Adolescents (n=12)
Genetic Testing (n=12)
Cascade Testing and Risk Notification of Families 
(n=15)
Management of Adults (n=25)
Management of Children and Adolescents (n=23)
Lipoprotein apheresis and related treatments (n=16)
Organisation and Development of Care (n=15)
All Components of the Guidance (n=140)
Class of Recommendation = 1 Class of Recommendation = 2 Class of Recommendation = 3
Levels of Evidence:
0% 20% 40% 60% 80% 100%
Phenotypic Detection of Index cases: Screening and 
Testing Strategies (n=12)
Diagnosis and Assessment of Adults (n=10)
Diagnosis and Assessment of Children and 
Adolescents (n=12)
Genetic Testing (n=12)
Cascade Testing and Risk Notification of Families 
(n=15)
Management of Adults (n=25)
Management of Children and Adolescents (n=23)
Lipoprotein apheresis and related treatments (n=16)
Organisation and Development of Care (n=15)
All Components of the Guidance (n=140)
Level of Evidence = A Level of Evidence = B Level of Evidence = C
aThe percentages refer to the aggregate of all the statements contributing to each component of the guidance shown in Tables 1 to 9; numbers in brackets refer to
the number of individual recommendations for each component.
bThe published works used as evidence for recommendations are listed and referenced in the Supplementary Material.
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Appendix D. The Dutch Lipid Clinic Network criteria for making the phenotypic diagnosis of FH in adult index cases.a,b
Criteria Score
Section 1: Family history
First degree relative with known premature coronary and/or vascular disease (men aged ,55 yr, women
aged ,60 yr)
OR First degree relative with known LDL-cholesterol above the 95th percentile for age and gender
1
First degree relative with tendinous xanthomata and/or arcus cornealis
OR Children aged ,18 yr with LDL-cholesterol above the 95th percentile for age and gender
2
Section 2: Clinical history
Patients with premature coronary artery disease (men aged ,55 yr, women aged ,60 yr) 2
Patients with premature cerebral or peripheral vascular disease (men aged ,55 yr, women aged ,60 yr) 1
Section 3: Physical examination
Tendinous xanthomata 6
Arcus cornealis before 45 yr of age 4











aFor online use, please access the FH Australasia Network calculator at https://www.athero.org.au/fh/calculator/.
bThese criteria should not be used to diagnose FH in children or adolescents (see 3.5 in Table 3).
cNote that only the highest score in each section is chosen to add up to the total score, to a maximum of 18.
dIf pre-treatment LDL-cholesterol is not available, use the FH Australasia Network’s online calculator (https://www.athero.org.au/fh/calculator/) to derive
LDL-cholesterol by adjusting value for cholesterol-lowering medication.
eTo convert LDL-cholesterol from mmol/L to mg/dL, multiply by 38.67.
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Appendix E. Lifestyle factors, clinical conditions and drugs that may increase plasma LDL-cholesterol concentrations.
Lifestyle factors
Excess energy intake

























Fibric acids (in severe hypertriglyceridaemia)
Omega-3 fatty acids (in severe hypertriglyceridaemia)
For further information, see the FH Australasia Network (https://www.athero.org.au/fh/health-professionals/secondary-causes-of-hypercholesterolaemia/)
and Heart UK (https://www.heartuk.org.uk/genetic-conditions/secondary-hyperlipidaemia) websites.
Adapted from Jacobson et al. (2015) [46].
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to genec and LDL-
cholesterol tesng 
LDL-cholesterol tesng 
Index case  
Carrier of a gene variant of known pathogenicity and/or  
probable/definite phenotypic FH by the Dutch Lipid Clinic Network criteria 
Counselling of biological relaves 
Offer appropriate tesng to biological 
relaves and proceed as above 
No consent/assent 
to genec tesng 
Genec and  
LDL-cholesterol tesng 




 FH variant  
present 
No consent/assent 
to genec or LDL-
cholesterol tesng 
Discuss risk noficaon of biological relavesa 
Discuss risk noficaon of biological relavesa 
FH variant  
not present 
FH excluded 
Monitor relave if LDL-
cholesterol elevated  
aConsistent with relevant local legislation and institutional guidelines
bAccording to age- and gender-specific plasma LDL-cholesterol concentrations published by Starr et al. [76] (see Appendix G).
Abbreviations: FH, familial hypercholesterolaemia; LDL, low density lipoproteins
Adapted from Watts et al. (2011) [17].
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Appendix G. Plasma low density lipoproteins (LDL)-cholesterol concentrations and thresholds (mmol/L)a, based on age
and gender, for making a diagnosis of familial hypercholesterolaemia (FH) during cascade testing of first-degree relatives of
a patient with FH.




0 to 14 15 to 24 25 to 34 35 to 44 45 to 54 55 and older 0 to 14 15 to 24 25 to 34 35 to 44 45 to 54 55 and older
5.5 5.5 5.5 5.5 5.5 5.5 5.5 5.5 5.5 5.5 5.5 5.5
5.4 5.4 5.4 5.4 5.4 5.4 5.4 5.4 5.4 5.4 5.4 5.4
5.3 5.3 5.3 5.3 5.3 5.3 5.3 5.3 5.3 5.3 5.3 5.3
5.2 5.2 5.2 5.2 5.2 5.2 5.2 5.2 5.2 5.2 5.2 5.2
5.1 5.1 5.1 5.1 5.1 5.1 5.1 5.1 5.1 5.1 5.1 5.1
5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0
4.9 4.9 4.9 4.9 4.9 4.9 4.9 4.9 4.9 4.9 4.9 4.9
4.8 4.8 4.8 4.8 4.8 4.8 4.8 4.8 4.8 4.8 4.8 4.8
4.7 4.7 4.7 4.7 4.7 4.7 4.7 4.7 4.7 4.7 4.7 4.7
4.6 4.6 4.6 4.6 4.6 4.6 4.6 4.6 4.6 4.6 4.6 4.6
4.5 4.5 4.5 4.5 4.5 4.5 4.5 4.5 4.5 4.5 4.5 4.5
4.4 4.4 4.4 4.4 4.4 4.4 4.4 4.4 4.4 4.4 4.4 4.4
4.3 4.3 4.3 4.3 4.3 4.3 4.3 4.3 4.3 4.3 4.3 4.3
4.2 4.2 4.2 4.2 4.2 4.2 4.2 4.2 4.2 4.2 4.2 4.2
4.1 4.1 4.1 4.1 4.1 4.1 4.1 4.1 4.1 4.1 4.1 4.1
4.0 4.0 4.0 4.0 4.0 4.0 4.0 4.0 4.0 4.0 4.0 4.0
3.9 3.9 3.9 3.9 3.9 3.9 3.9 3.9 3.9 3.9 3.9 3.9
3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8
3.7 3.7 3.7 3.7 3.7 3.7 3.7 3.7 3.7 3.7 3.7 3.7
3.6 3.6 3.6 3.6 3.6 3.6 3.6 3.6 3.6 3.6 3.6 3.6
3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5
3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4
3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3
3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2
3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1
3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0
MALE FEMALE
Age Age
aTo convert LDL-cholesterol from mmol/L to mg/dL, multiply mmol/L by 38.67.
Adapted from Starr et al. (2008) [76].
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Appendix H. Selected organisations and related online resources for health care providers managing patients with familial
hypercholesterolaemia (FH).
Organisation Web address Description
National Heart
Foundation.
www.heartfoundation.org.au Leading Australian charity that provides resources for health
professionals and the community on all aspects of primary and
secondary prevention of cardiovascular disease.
FH Australasia
Network.
www.athero.org.au/fh Network of clinicians and scientists from across Australia. Activities
include the development of management guidelines, information
sessions for clinicians, the establishment of various services around





Website of the first support group in Australia for families with
familial hypercholesterolaemia (FH); provides relevant information




www.genetics.edu.au Provides genetic educational resources for individuals and families
affected by genetic conditions and also provides education and




www.genomicsinfo.org.au National body that funds and conducts research to build evidence to
inform the integration of genomic medicine into mainstream health
care.
FH Europe. www.fheurope.org Leading charity that focusses on sharing information and best
practice across Europe, working with experts to focus topics of
interest to the patients and families and support the development of
newer or smaller patient groups.
British Heart
Foundation.
www.bhf.org.uk Leading British foundation that provides resources for health
professionals and patients, including informative videos on a wide
spectrum of conditions and risk factors.
Heart UK - The
Cholesterol
Charity.
www.heartuk.org.uk Leading UK cholesterol charity that provides resources for health
professionals, patients and families on all aspects of the detection
and management of FH.
Wales FH
Testing Service.
www.fhwales.co.uk Exemplar FH service in Wales that provides useful information and




www.phgfoundation.org International foundation that publishes reports on the role of









www.lipid.org US based multidisciplinary society providing education, training,
guidelines and position statements on all aspects of the detection and
management of dyslipidaemia and related disorders.
Learn Your
Lipids, NLA.
www.learnyourlipids.com Information for patients with dyslipidaemia, including FH, as





www.pcna.net Leading nursing organisation dedicated to preventing and managing
cardiovascular disease.
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